Editas Medicine, Inc. and Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer of the Company, agreed that Dr. Shearman will step down as Chief Scientific Officer effective March 31, 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.9 USD | +5.17% |
|
+20.06% | -41.81% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.81% | 461M | |
+25.36% | 46.56B | |
+45.38% | 41.67B | |
+0.92% | 41.16B | |
+30.65% | 32.4B | |
+22.13% | 28.18B | |
-6.35% | 28.1B | |
+48.73% | 14.52B | |
+48.33% | 13.74B | |
+3.49% | 12.17B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023